SOPs for BA-BE Studies V 2.0

To establish a standardized approach for the documentation of clinical data at source and its subsequent entry into Case Report Forms (CRFs) or electronic systems during the clinical phase of Bioavailability/Bioequivalence (BA/BE) studies, ensuring traceability, accuracy, and compliance with ALCOA+ principles.
Click to read the full article.

To outline a clear and systematic approach for identifying, responding to, and managing medical emergencies that occur in Bioequivalence (BE) units during the conduct of BA/BE studies, ensuring subject safety, prompt medical intervention, and documentation in compliance with ethical and regulatory standards.
Click to read the full article.

To establish a uniform procedure for enforcing post-dosing restrictions and conducting medical observations of volunteers during the clinical phase of BA/BE studies, ensuring subject safety and compliance with study protocol and regulatory expectations.
Click to read the full article.

To define a standardized and compliant procedure for the transport of plasma samples collected during BA/BE studies from the clinical site to the designated bioanalytical laboratory, maintaining sample integrity, cold chain, and traceability throughout the process.
Click to read the full article.

To define a standardized procedure for documenting concomitant medication usage by volunteers during the clinical phase of Bioavailability/Bioequivalence (BA/BE) studies, ensuring safety monitoring, accurate data interpretation, and compliance with GCP and regulatory standards.
Click to read the full article.

To define a standardized and regulatory-compliant procedure for managing incidents of vomiting or spitting of the administered drug in volunteers post-dosing during BA/BE studies, ensuring proper documentation, subject care, and evaluation of study validity.
Click to read the full article.

To establish a uniform procedure for monitoring and ensuring compliance of subjects with protocol-defined activities and restrictions during the clinical phase of Bioavailability/Bioequivalence (BA/BE) studies to maintain data integrity and subject safety.
Click to read the full article.

To outline the procedure for maintaining the integrity of blinding during the conduct of blinded Bioavailability/Bioequivalence (BA/BE) studies to ensure unbiased assessment, compliance with regulatory requirements, and valid interpretation of study data.
Click to read the full article.

To define the procedure for preparing, reviewing, and finalizing interim clinical monitoring reports during Bioavailability/Bioequivalence (BA/BE) studies. These reports ensure ongoing compliance, identify potential issues, and support timely decision-making.
Click to read the full article.

To define the process for preparing the clinical site and documentation for audits conducted during or after the clinical phase of Bioavailability/Bioequivalence (BA/BE) studies, including internal QA audits, sponsor audits, and regulatory inspections.
Click to read the full article.